Dai­ichi Sankyo shuts down Plexxikon sub­sidiary to stream­line En­her­tu, ADC de­vel­op­ment

Dai­ichi Sankyo is say­ing good­bye to one of its long­time sub­sidiaries.

The multi­na­tion­al phar­ma com­pa­ny an­nounced Wednes­day it will shut down all op­er­a­tions of Plexxikon, which it ac­quired in a $935 mil­lion buy­out back in 2011. In a re­lease, Dai­ichi said it’s clos­ing Plexxikon’s of­fices to “max­i­mize its R&D in­vest­ment” in its ma­jor can­cer drug En­her­tu as well as two oth­er ADC pro­grams, Da­to-DXd and HER3-DXd.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER